Alar Pharmaceuticals Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018 - 2017
Period Ending	Sep '24 Sep 9, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018 - 2017
Market Capitalization	12,325	11,942	6,555	2,608	2,793	-	Upgrade
Market Cap Growth	72.34%	82.17%	151.37%	-6.63%	-	-	Upgrade
Enterprise Value	9,879	11,326	6,046	2,053	2,171	-	Upgrade
Last Close Price	184.50	208.35	114.37	45.50	48.73	-	Upgrade
PE Ratio	27.08	31.05	-326.76	-40.38	-17.03	-	Upgrade
PS Ratio	24.10	25.45	8193.75	-	4655.00	-	Upgrade
PB Ratio	4.97	13.31	12.74	4.88	4.67	-	Upgrade
P/FCF Ratio	49.15	30.06	-192.31	-40.09	-19.63	-	Upgrade
P/OCF Ratio	65.86	29.59	-198.96	-41.09	-19.68	-	Upgrade
EV/Sales Ratio	21.05	24.14	7557.22	-	3617.60	-	Upgrade
EV/EBITDA Ratio	25.68	29.22	-136.89	-22.60	-12.86	-	Upgrade
EV/EBIT Ratio	25.92	29.38	-129.94	-22.00	-12.71	-	Upgrade
EV/FCF Ratio	39.40	28.51	-177.37	-31.56	-15.25	-	Upgrade
Debt / Equity Ratio	0.00	0.00	0.01	0.00	0.00	0.01	Upgrade
Debt / EBITDA Ratio	0.00	0.00	-	-	-	-	Upgrade
Debt / FCF Ratio	0.00	0.00	-0.08	-0.01	-0.01	-0.03	Upgrade
Asset Turnover	0.29	0.63	0.00	-	0.00	-	Upgrade
Quick Ratio	39.50	11.98	90.70	116.51	135.92	50.27	Upgrade
Current Ratio	39.65	12.08	92.66	118.67	143.31	53.93	Upgrade
Return on Equity (ROE)	28.12%	54.21%	-3.79%	-11.34%	-36.17%	-30.19%	Upgrade
Return on Assets (ROA)	14.83%	32.22%	-5.47%	-10.19%	-26.68%	-16.35%	Upgrade
Return on Capital (ROIC)	16.06%	34.04%	-5.53%	-10.27%	-26.90%	-16.95%	Upgrade
Earnings Yield	3.69%	3.20%	-0.30%	-2.46%	-5.11%	-	Upgrade
FCF Yield	2.03%	3.33%	-0.52%	-2.49%	-5.10%	-	Upgrade
Dividend Yield	0.82%	0.72%	-	-	-	-	Upgrade
Buyback Yield / Dilution	-7.66%	-0.09%	-	-14.21%	-42.59%	-27.77%	Upgrade
Total Shareholder Return	-6.84%	0.63%	-	-14.21%	-42.59%	-27.77%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.